Skip to main content
. 2004 Jun;19(6):684–691. doi: 10.1111/j.1525-1497.2004.30016.x

Table 2.

Patient Characteristics in the Derivation and Validation Sets for Patients Prescribed ACE inhibitors

Characteristic Derivation Set (N= 1,125) Validation Set (N= 567)
Mean age, y ± SD 58.9 ± 13.9 57.9 ± 14.1
Male, n(%) 476 (42) 210 (37)
Ethnicity
 Caucasian, n(%) 498 (44) 232 (41)
 African American, n(%) 303 (27) 160 (28)
 Latino, n(%) 175 (16) 103 (18)
 East Asian (Chinese, Korean, Japanese), n(%) 17 (1.5) 4 (0.7)
Smoking Status
 Current smoker, n(%) 125 (11) 72 (13)
 Past smoker, n(%) 284 (25) 154 (27)
 Never smoked, n(%) 716 (64) 341 (60)
History of other ACE inhibitors, n(%) 271 (24) 108 (19)
History of ACE inhibitor-induced cough, n(%) 24 (2) 8 (1)
History of ACE inhibitor-induced angioedema, n(%) 1 (0.1) 1 (0.2)
Medical Conditions
 Hypertension, n(%) 960 (85) 482 (85)
 Diabetes mellitus, n(%) 407 (36) 197 (35)
 Coronary artery disease, n(%) 224 (20) 106 (19)
 Congestive heart failure, n(%) 86 (8) 48 (8)
 Chronic obstructive pulmonary disease, n(%) 39 (3) 24 (4)
 Asthma, n(%) 119 (11) 50 (9)
 Other respiratory diseases, n(%) 15 (1) 9 (2)
 Depression/anxiety, n(%) 314 (28) 163 (29)
 Other psychiatric diseases, n(%) 42 (4) 27 (5)
 Hemodialysis, n(%) 14 (1) 6 (1)
 Creatinine ≥1.6 mg/dL, n(%) 66 (6) 29 (5)
Concurrent Medications
 Diuretics, n(%) 436 (39) 208 (37)
 Beta-blockers, n(%) 408 (36) 208 (37)
 Calcium antagonists, n(%) 174 (15) 81 (14)
 Low dose (≤325 mg/day) aspirin, n(%) 373 (33) 177 (31)
 High dose (>325 mg/day) aspirin, n(%) 1 (0.1) 2 (0.4)
 Nonsteroidal anti-inflammatory drugs, n(%) 178 (16) 98 (17)
 Cyclo-oxygenase-2 inhibitors, n(%) 64 (6) 28 (5)
ACE inhibitor-induced cough, n(%) 130 (12) 72 (13)

ACE, angiotensin-converting enzyme; SD, standard deviation.